Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients

Merlyna Savitri, Ugroseno Yudho Bintoro, Made Putra Sedana, Muhammad Noor Muhammad, Pradana Zaky Romadhon, Putu Niken Ayu Amrita, Andi Yasmin Wijaya, Winona May Hendrata, Ami Ashariati Prayogo

Abstract


BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population.

METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer.

RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity.

CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.

KEYWORDS: biomarker, breast cancer, circulating plasma, liquid biopsy, miRNA-21


Full Text:

PDF

References


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424, CrossRef.

Forman D, Ferlay J, Steward BW, Wild CP. The global and regional burden of cancer. In: Stewart BW, Wild CP, editors. World Cancer Report 2014. Geneva: WHO Press; 2014, article.

Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017; 172: 34-49, CrossRef.

Sandya Rani GSB, Bitla A. Breast cancer diagnosis – role of biomarkers. J Clin Sci Res. 2017; 6: 225-36, CrossRef.

Kharkwal S, Sameer A, Mukherjee A. Triple test in carcinoma breast. J Clin Diagnostic Res. 2014; 8: NC09-NC11, CrossRef.

Kahraman M, Röske A, Laufer T, Fehlmann T, Backes C, Kern F, et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Sci Rep. 2018; 8: 11584, CrossRef.

Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care. 2011; 6: 199-207, CrossRef.

Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow up and monitoring therapeutic response in breast cancer patients. Anticancer Res. 1999; 19: 3511-5, PMID.

Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013; 25: 743-8, CrossRef.

Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015; 10: e0133830, CrossRef.

Pissaia A, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc. 2009; 41: 682-4, CrossRef.

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel biomarkers for breast cancer. J Oncol. 2009; 2009: 950201, CrossRef.

Pan X, Wang ZX, Wang R. MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol Ther. 2010; 10: 1224–32, CrossRef.

Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino- Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013; 34: 163-9, CrossRef.

Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivotumor growth. Breast Cancer Res. 2011; 13: R2, CrossRef.

Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor diseasefree survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2009; 117: 131-40, CrossRef.

Fu SW, Chen L, Man YG. miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer. 2011; 2: 116-22, CrossRef.

Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012; 5: 7-13, CrossRef.

Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2008; 13: 447, CrossRef.

Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015; 2015: 731479, CrossRef.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105: 10513-8, CrossRef.

Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers for management of breast cancer patients. Biomed Res Int. 2013; 2013: 685641, CrossRef.

Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, et al. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res. 2012; 40: 6821-33, CrossRef.

Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer (Review). Biomed Reports. 2016; 5: 395-402, CrossRef.

Ma X, Choudhury SN, Hua X, Dai Z, Li Y. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. Carcinogenesis. 2013; 34: 1216-23, CrossRef.

Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008; 18: 350-9, CrossRef.

Jiang LH, Ge MH, Hou XX, Cao J, Hu SS, Lu XX, et al. miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma. Lab Investig. 2015; 95: 1398-408, CrossRef.

Ibrahim H, Fattah A, Mahmoud NH, Elzoghby DM, Matar MM, Elshaer IMM. Clinical utility of circulating microRNA-21 in breast Cancer. Egypt J Hosp Med. 2018; 71: 2950-5, article.

Badr FM. Potential role of miR-21 in breast cancer diagnosis and therapy. Biotechnol Biomed Eng. 2016; 3: 1068, article.

Toraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer Patients. Mol Diagn Ther. 2015; 19: 179-90, CrossRef.

Han JG, Jiang YD, Zhang CH, Yang YM, Pang D, Song YN, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res. 2017; 92: 55-66, CrossRef.




DOI: https://doi.org/10.18585/inabj.v12i2.1142

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute